Skip to main content

Advertisement

SpringerLink
Log in

Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Matrix metalloproteinases (MMPs) are frequently expressed in malignant tumors and play an important role in tumor invasion and metastasis. The aim of this study was to evaluate role of serum MMP-2 and MMP-7 levels in patients with ovarian cancer. Serum levels of MMP-2 and MMP-7 were measured in 28 patients with ovarian carcinoma, 2 with borderline ovarian tumors, 10 with non-malignant gynecological disease and 30 healthy women by Enzyme-Linked Immunosorbent Assay (ELISA). Serum MMP-7 level was significantly (10.24 ± 1.35 ng/ml) higher in the patients with ovarian malign tumors than healthy controls (3.29 ± 1.64 ng/ml) (P < 0.05). Postoperative levels of MMP-7 (7.68 ± 1.17 ng/ml) were significantly lower in patients with malign ovarian tumors than those of preoperative level (10.24 ± 1.35 ng/ml) (P < 0.05). Serum MMP-2 levels were significantly lower in the patients with ovarian malign tumors (227.51 ± 9.91 ng/ml) than those in the healthy controls (279.12 ± 73 ng/ml) (P < 0.05). There was no significant difference in serum levels of MMP-2 and MMP-7 in patients with benign ovarian disease when compared to healthy controls and patients with malignant disease (P > 0.05). As a conclusion, MMP-7 can be a useful serum marker to show disease activity in malignant ovarian tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Westerlund A, Apaja-Sarkkinen M, Höyhtya M, Puistola U, Turpeenniemi-Hujanen T. Gelatinase A-immunoreactive protein in ovarian lesions-prosnoctic value in epithelial ovarian cancer. Gynecol Oncol 1999;5:91–8.

    Article  Google Scholar 

  2. Lengyel E, Schmalfeldt B, Konik E, Späthe K, Härting K, Fenn A, Berger U, Fridman R, Schmitt M, Preehtel D, Kuhn W. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 2001;82:291–8.

    Article  PubMed  CAS  Google Scholar 

  3. Wu X, Li H, Kang L, Li L, Wang W, Shan B. Activated matrix metalloproteinase-2- a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol 2002;84 (1):126–34.

    Article  PubMed  CAS  Google Scholar 

  4. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999;13:781–92.

    PubMed  CAS  Google Scholar 

  5. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463–516.

    Article  PubMed  CAS  Google Scholar 

  6. Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E, Puricelli L. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 2003;106:745–51.

    Article  PubMed  CAS  Google Scholar 

  7. Kermorgant S, Aparicio T, Dessirier V, Lewin MJ, Lehy T. Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement. Carcinogenesis 2001;22:1035–42.

    Article  PubMed  CAS  Google Scholar 

  8. Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 2003;22:145–52.

    Article  PubMed  CAS  Google Scholar 

  9. Wang FQ, So J, Reierstad S, Fishman DA. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer 2005;114(1):19–31.

    Article  PubMed  CAS  Google Scholar 

  10. Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, Marmol M, Gallardo E, Maria Auge J, Longaron R, Martinez-Fernandez A, Molina R, Castells A, Gascon P. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer 2007 May 8; [Epub ahead of print].

  11. Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S, Nakajima M. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 1996;78:2379–87.

    Article  PubMed  CAS  Google Scholar 

  12. Sheen-Chen SM, Chen HS, Eng HL, Sheen CC, Chen WJ. Serum levels of matrix metalloproteinase 2 in patients with breast cancer. Cancer Lett 2001;173:79–82 .

    Article  PubMed  CAS  Google Scholar 

  13. Liu SC, Yang SF, Yeh KT, Yeh CM, Chiou HL, Lee CY, Chou MC, Hsieh YS. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clin Chim Acta 2006;371:92–6.

    Article  PubMed  CAS  Google Scholar 

  14. Oberg A, Hoyhtya M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000;20:1085–91.

    PubMed  CAS  Google Scholar 

  15. Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN, Brentani MM. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis 1998;16:577–85.

    Article  PubMed  CAS  Google Scholar 

  16. Kawano N, Osawa H, Ito T, Nagashima Y, Hirahara F, Inayama Y, Nakatani Y, Kimura S, Kitajima H, Koshikawa N, Miyazaki K, Kitamura H. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol 1997;28:613–22.

    Article  PubMed  CAS  Google Scholar 

  17. Coskun U, Yamac D, Gulbahar O, Sancak B, Karaman N, Ozkan S. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response? Neoplasma 2007;54:348–52.

    PubMed  CAS  Google Scholar 

  18. F.I.G.O. News. Int J Gynecol Obstet 1989;28:189–93.

    Google Scholar 

  19. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 2005;11:5158–66.

    Article  PubMed  CAS  Google Scholar 

  20. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64(2):327–36.

    Article  PubMed  CAS  Google Scholar 

  21. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996;56:190–6.

    PubMed  CAS  Google Scholar 

  22. Shima I, Sasaguri Y, Kusukawa J, Yamana H, Fujita H, Kakegawa T, Morimatsu M. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study. Cancer 1992;70:2747–53.

    Article  PubMed  CAS  Google Scholar 

  23. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, Shriver CD. Circulating MMP2 and MMP9 in breast cancer—potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 2006;119:1403–11.

    Article  PubMed  CAS  Google Scholar 

  24. Sasaki H, Yukiue H, Kobayashi Y, Kaji M, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y. Elevated serum pro-MMP2 levels in patients with stage IV thymoma. Surg Today 2002;32:482–6.

    Article  PubMed  CAS  Google Scholar 

  25. Sillanpaa SM, Anttila MA, Voutilainen KA, Ropponen KM, Sironen RK, Saarikoski SV, Kosma VM. Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression. Int J Cancer 2006;119:1792–9.

    Article  PubMed  CAS  Google Scholar 

  26. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, de e Nictolis M, Garbisa S, Masiero L, Romanini C, Graziella B. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res. 1995;15:2799–804.

    PubMed  CAS  Google Scholar 

  27. Demeter A, Sziller I, Csapo Z, Olah J, Keszler G, Jeney A, Papp Z, Staub M. Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer Anticancer Res 2005;25:2885–9.

    Google Scholar 

  28. Komorowski J, Pasieka Z, Jankiewicz-Wika J, Stepien H. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. Thyroid 2002;12:655–62.

    Article  PubMed  CAS  Google Scholar 

  29. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994 ;94:2493–503.

    Article  PubMed  Google Scholar 

  30. Tayebjee MH, Lip GY, MacFadyen RJ. Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance. Curr Med Chem 2005;12:917–25.

    Article  PubMed  CAS  Google Scholar 

  31. Lewandowski KC, Komorowski J, O’Callaghan CJ, Tan BK, Chen J, Prelevic GM, Randeva HS. Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:1173–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Gazi University Medical School, Ankara, Turkey

    Ayla Acar, Anil Onan & Haldun Guner

  2. Department of Medical Oncology, Gazi University Medical School, Ankara, Turkey

    Aytug Uner

  3. 40. cadde 444.sokak, 5/5 Ebru Apt., Çukurambar/100.Yıl, Ankara, Turkey

    Ugur Coskun

  4. Department of Immunology, Gazi University Medical School, Ankara, Turkey

    Umit Bagriacik

  5. Department of Obstetrics and Gynecology, Ankara Onkoloji Hospital, Ankara, Turkey

    Funda Atalay

  6. Department of Radiation Oncology, Gazi University Medical School, Ankara, Turkey

    Diclehan Kilic Unsal

Authors
  1. Ayla Acar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anil Onan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ugur Coskun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aytug Uner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Umit Bagriacik
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Funda Atalay
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Diclehan Kilic Unsal
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Haldun Guner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ugur Coskun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Acar, A., Onan, A., Coskun, U. et al. Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer . Med Oncol 25, 279–283 (2008). https://doi.org/10.1007/s12032-007-9031-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-007-9031-1

Keywords

Search

Navigation